910777-83-2

Upstream product

• 767-90-8 (2-ethylphenyl)methanol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 1410807-67-8 4-(2-ethylphenylmethyl)-5-isopropyl-1H-pyrazol-3-yl 2,3,4,6-tetra-O-acetyl-β-d-glucopyranoside 
• 1410807-90-7 4-(2-ethylphenylmethyl)-5-isopropyl-1H-pyrazol-3-yl β-d-glucopyranoside 
• 1410807-21-4 4-(2-ethylphenylmethyl)-1,2-dihydro-5-isopropyl-3H-pyrazol-3-one 
• 1410806-88-0 C₁₆H₂₂O₃ 
• 910777-82-1 6-bromo-N-[(2-ethylphenyl)methyl]-2,3-dimethylimidazo[1,2-a]pyridin-8-amine 

Relevant academic research and scientific papers

COMBINATION TREATMENTS COMPRISING IMIDAZOPYRAZINONES FOR THE TREATMENT OF PSYCHIATRIC AND/OR COGNITIVE DISORDERS

The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of psychiatric and/or cognitive disorders such as for example Attention Deficit Hyperactivity Disorder (ADHD), depression, anxiety, narcolepsy, schizophrenia, cognitive impairment or cognitive impairment associated with schizophrenia (CIAS). Separate aspects of the invention are directed to the combined use of said compounds for the treatment of psychiatric and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of psychiatric and/or cognitive disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES

The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of neurodegenerative disorders such as for example Alzheimer's Disease, Parkinson's Disease or Huntington's Disease. Separate aspects of the invention are directed to the combined use of said compounds for the treatment of neurodegenerative and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of neurodegenerative disorders.

IMIDAZOPYRAZINONES AS PDE1 INHIBITORS

The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia

Sodium glucose co-transporter 1 (SGLT1) plays a dominant role in the absorption of glucose in the gut and is considered a promising target in the development of treatments for postprandial hyperglycemia. A series of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyran